Medical University  |  MUSC Hospital  |  Directory  |  A-Z Index

        

             Welcome to the College of Health Professions


MUSC Home     
Alcohol Research Center Home

Overview
Theme and Philosophy 
Background 
Location and Contacts 

Leadership
Director   
Scientific Director
Program Advisory Committee   

Core Components
Administrative Core
Scientific  Enrichment
Pilot Component    
Shared Core 

Clinical Research Components
Drs. Anton & Myrick 
Drs. Danielson & Thomas

Basic Science Research Components
Drs. Griffin & Becker
Drs. Chandler & Lopez
Dr. Woodward



Component #4

Impulsivity and Drinking /Craving: Effect of a Dopamine Stabilizer Medication

Principal Investigator: Raymond Anton, M.D.
Co-Principal Investigator: Hugh Myrick, M.D. 
Co-Investigator: Konstantin Voronin, M.D., Ph.D.

In this research component, individual “trait-impulsivity” differences that might predict a risk for the development of alcohol dependence and/or risk for relapse have been identified and are being further investigated.

Findings in animals and humans suggest that a dysfunctional brain dopamine system underlies impulsive traits. Given that the dopamine system underlies both impulsivity and reward areas in the brain, it is not surprising that individuals high in trait-impulsivity show different brain regional activity to reward than individuals low in trait-impulsivity. Interestingly, these areas of activation in the brain are similar to what has been observed in non-treatment seeking alcoholics (NTSA) following the presentation of alcohol cues. We found that aripiprazole, a drug that is thought to “stabilize” the dopamine system, reduces drinking and blocks alcohol cue-induced activity in the ventral striatal area of the brain in NTSAs, and it does so most clearly in individuals with high trait-impulsivity.

The aim of this component is to replicate and extend this original finding with aripiprazole, in a medication group by trait-impulsivity group experimental design. In addition to studying the interaction of aripiprazole and trait-impulsivity, we will also systematically evaluate the role of trait-impulsivity and aripiprazole, per se, as main effects on drinking and craving using our well-validated, natural drinking, brain imaging, and other consumption paradigms. Finally, we will explore whether functional genetic variants in the brain dopamine system might underlie trait-impulsivity effects and/or aripiprazole response.


   

Investigators   
Events   
Addiction Seminars
Blood Alcohol Estimator Cards   

Research Study Participation   
Related Links 

Substance Abuse Training Programs   
 

 


ARC Intranet